Cepheid

The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.

Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time. 

The test measures hepatitis B viral DNA and is intended to be used to assess prognosis and response to antiviral therapies.

The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.

Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.

The court ruled that Roche's claims are patent-ineligible because they are "directed to a natural phenomenon and lack any inventive concept" for a patent.

The test detects and quantifies hepatitis C virus RNA and can be performed in approximately one hour. 

Testing with Cepheid's molecular TB assay can shorten the amount of time suspected patients need to be isolated and save thousands of dollars per patient.

The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.

The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.